SYK

RED FLAG: ABSENT

Stryker does not present immediate fatal risks: it generates robust operating cash flow ($5.04B in 2025), maintains investment-grade ratings, and shows no exposure to fraud or insolvency. The cyberattack that occurred in Q1 2026 was managed with impact limited to the quarter and does not alter the company’s structural profile.

AI DISRUPTION RISK: LOW

Artificial intelligence acts as a business accelerator for Stryker, not as a substitution threat. The Mako robotic platform benefits from AI for pre-operative planning and surgical optimization. The core business — physical FDA-certified medical devices, implants, and systems integrated into hospital clinical workflows — is protected by regulatory barriers that make digital disruption extremely difficult in the short and medium term.

B1.1 — Leadership and systemic role: 8.75

Stryker is one of the three global leaders in medical devices, with a dominant position in orthopedic robotic surgery through the Mako platform. Its market share in robotic orthopedics in U.S. hospitals is among the highest in the industry, alongside a broad presence in neurotechnology, trauma, endoscopy, and surgical instruments. The company’s systemic role in the modernization of global operating rooms — with multi-year hospital contracts and an installed base that is difficult to displace — gives it structural centrality in the healthcare supply chain that goes beyond any single product.

B1.2 — Customers and barriers to entry: 8.50

Barriers to entry are among the highest in the industrial universe: mandatory FDA approval for each device, intensive surgical training cycles on Mako systems, deep integration into hospital workflows, and prohibitive replacement costs. Multi-year contracts with hospitals and healthcare systems create operational lock-in that keeps churn structurally low. New entrants must face years of development, clinical trials, and regulatory processes before they can compete.

B1.3 — Business economics: 8.50

In FY2025 Stryker exceeded $25B in revenue with organic growth of 10.3%, adjusted operating margin of 26.3%, and adjusted EPS of $13.63 (+11.8% year-on-year). ROIC remains structurally above 15%. The recurring component of the business — consumables and services linked to the Mako installed base — provides predictability to cash flows. GAAP margins are affected by acquisition amortization, but the real cash profile is that of a high-quality compounder.

B1.4 — Balance sheet and resilience: 8.00

Cash generation is solid: 2025 cash from operations of $5.04B, FCF TTM of $4.28B, and cash plus marketable securities of $4.10B. Long-term debt of $14.9B reflects the intensity of M&A activity in recent years (including the acquisition of Inari Medical). Interest coverage remains widely sustainable (>8x) and the investment-grade rating is confirmed. Balance-sheet strength is real, with the only note of caution linked to leverage stemming from strategic acquisitions.

B2.1 — Sector cycle: 7.00

The MedTech sector is going through a generally favorable phase: global surgical volumes are in structural recovery post-pandemic, revisions to aggregate sector earnings estimates are generally positive, hospital demand remains robust, and credit stress in the sector is contained. The main drag is the geopolitical and regulatory regime: tariffs introduced in 2026 weigh on the margins of companies with international supply chains, with impact estimated by Stryker management at around $400M annually. Three factors out of five are clearly positive, with the fourth partially favorable.

B2.2 — Structural trends: 8.50

Long-term megatrends are among the strongest in the investable universe: demographic aging in Western and Asian populations is unstoppable, the expansion of the global middle class increases access to surgical care, and the transition toward minimally invasive and robot-assisted surgery is accelerating rapidly. The 5-10 year horizon for the Medical Devices sector is structurally positive, with continuously expanding TAM.

B2.3 — Competitive positioning in the cycle: 8.25

Stryker is systematically outperforming direct competitors in the current phase. 2026 guidance calls for organic growth of 8.0-9.5% and adjusted EPS of $14.90-$15.10, confirming robust momentum. The resilience of recurring revenues (Mako consumables, maintenance contracts) softens cyclicality. The recent consolidation through Inari Medical broadens exposure to the neurovascular segment, strengthening portfolio diversification.

B2.4 — Specific exogenous risks: 6.50

The main risks are exogenous and well identified: estimated tariff impact of ~$400M in 2026, FX exposure on international revenues, cyber risk (Q1 2026 episode already contained but indicative of operational vulnerability), and potential slowdown in hospital capex budgets in a context of still-elevated rates. None of these risks is binary or structurally threatening to the long-term thesis, but their combination justifies a cautious stance in the short term.

B3.1 — Intrinsic Fair Value: 5.94

DCF fair value estimates show contained dispersion and a mixed distribution around the current price, with two sources above and two below the market price. The overall picture indicates valuation in the fair value area with a slight discount.

The weighted fair value of $339.37 is above the current price of $330.56, with a discount of 2.6% — insufficient to qualify as structural undervaluation, but not in premium territory. The stock prices in very high quality at a price that leaves only a limited margin of safety on intrinsic models.

> 📐 Discount 2.6% → base score 5.50 | dispersion 36.4% MIXED → penalty 0.00 | Excellence Premium +0.44 (Business Score 8.44 > 8.00) → final score 5.94

B3.2 — Analyst Consensus: 7.02

Sell-side consensus is positive but not unanimous: 60.4% of analysts have a Buy recommendation, with an average target of $425.10 implying 28.6% upside versus the current price. The total absence of Sell ratings signals broad conviction in business quality; the significant Hold share (39.6%) reflects concerns about the multiple and the technical phase. Consensus is expressed at the current price and already includes expectations of recovery from recent weakness.

> 📐 Consensus (29/48 Buy, 60.4%) → Consensus_Score 6.04 | upside +28.6% → Upside_Score 8.00 | weight w=0.50 (upside = U0) → B3.2 = 7.02

B3.3 — Relative valuation: 4.25

The 39.36x P/E TTM is slightly below the company’s 5-year historical average (~39.9x), but remains significantly above the average of Medical Devices peers (~25.4x). The AND condition required by the framework — P/E lower simultaneously than both history and peers — is not satisfied. The gap versus sector competitors is relevant (~55%), indicating that the market prices Stryker with a structural premium tied to business quality. This premium has historically been justified, but it limits multiple expansion potential and introduces compression risk in case of quarterly disappointments.

B3.4 — FCF & Net Shareholder Yield: 6.25

FCF TTM of $4.28B (cash from operations $5.04B minus capex $0.76B) on a market cap of $126.63B generates an FCF yield of 3.38%. Adding the dividend yield of 1.06% and a substantially neutral buyback component (modest net issuance), Net Shareholder Yield stands at 4.44%. Overall shareholder return is positive but not exceptional for a growth company of this quality, placing it in the middle range of the valuation scale.

Combined profile: Solid business, positive outlook, fair valuation.

Competitive Advantage and Moat

Stryker’s structural moat is built on hospital switching costs among the highest in the industrial universe — the Mako platform creates an ecosystem of training, consumables, and multi-year contracts that makes changing supplier economically and operationally prohibitive. The moat is expanding thanks to continuous innovation in surgical robotics, neurovascular, and intraoperative imaging, amplified by methodical bolt-on acquisitions that broaden portfolio coverage and cross-selling with hospital customers.

General Cycle and Competitive Dynamics

The MedTech sector is in an expansionary phase supported by favorable demographics and recovery in surgical volumes, with tariff dynamics as the main element of short-term uncertainty. Stryker competes with Intuitive Surgical, Medtronic, Zimmer Biomet, Johnson & Johnson, and Boston Scientific, while maintaining a position of relative strength thanks to superior operational execution and organic growth consistently above sector averages. Pricing power on premium devices remains intact even in inflationary environments.

Catalysts and Future Opportunities (Bull Case)

Key catalysts over the next 12-18 months include confirmation of 2026 guidance in Q1 results — the first test after the cyber episode — and the progressive penetration of Mako in international markets, where robotic adoption rates are still lower than in the United States. Full integration of Inari Medical in peripheral neurovascular represents a structural growth option with significant TAM still to penetrate. Analyst consensus with an average target of $425 implies almost 29% upside that would materialize with ordinary execution of the industrial plan.

Risks (Bear Case)

The main risk is valuation: a company trading at almost 40 times earnings admits no mistakes. A disappointing quarter — whether from tariff impacts above expectations, delays in Inari integration, or slower hospital volumes — could result in significant multiple compression. Second, the intensity of the M&A program increases operational complexity and introduces integration risks. Pressure on healthcare budgets in a context of still-elevated rates remains a cyclical headwind to hospital capex growth.

Solid business with high-quality fundamentals and robust sector outlook, but in acute technical decline with the stock close to the lows of the past 12 months and within a Falling Knife pattern in recent weeks. Valuation is fair with no significant margin of safety at current prices. WAIT FOR STABILIZATION.

Why it could be an opportunity

Stryker is a top-tier medtech compounder with structurally above-average organic growth, expanding FCF, and analyst consensus that embeds almost 29% upside from the current price. The recent drop from the $404 high has brought the stock into an area where weighted fair value is slightly above the current price, marginally improving the risk/reward profile versus prior months. Possible technical stabilization and confirmation of guidance in Q1 2026 could represent the catalyst for re-entry into the analysis.

Why it could be a risk

The stock is in a Falling Knife pattern with %Range_52w at 13% and %Range_15d at 16% — a sign of still-active selling pressure that discourages exposure before confirmed stabilization. The 39x P/E remains significantly above sector peers, exposing the stock to multiple compression risk in case of quarterly disappointment. The estimated $400M tariff impact in 2026 is not yet fully priced into models, and the margin of safety offered by DCF models is limited.

Price Target Table

This analysis is produced by the Score³ system for informational purposes only and does not constitute financial advice, a solicitation to invest, or a trading or investment recommendation. Data is collected from public sources and may contain errors or delays. Fair value estimates and price targets are model-based projections subject to significant uncertainty and do not represent certain forecasts. Investing involves risks, including the possible loss of invested capital. Always verify critical data against primary sources before making any investment decision. Past performance is not indicative of future results.